Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the global burden of disease study 2023
| dc.contributor.author | Cousin, Ewerton | |
| dc.contributor.author | Okonji,Osarenti. Christabel | |
| dc.contributor.author | Nascimento, Bruno Ramos | |
| dc.date.accessioned | 2026-06-23T10:44:06Z | |
| dc.date.available | 2026-06-23T10:44:06Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Background: Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi, primarily transmitted by infected bugs, but also through contaminated food, transfusions, congenital transmission, and organ transplantation. Chagas disease has acute and chronic phases; the chronic phase can occur decades after infection, leading to complications such as heart failure, arrhythmias, and megaviscera. Accurate mortality and morbidity estimates are hindered by under-reporting and misclassification. Comprehensive and updated estimates are needed to improve global assessments of Chagas disease burden. We aim to provide a comprehensive description of global and regional burden of Chagas disease and its trends from 1990 to 2023. Methods: In this systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, we produced estimates of Chagas disease deaths, years of life lost (YLLs), prevalence, incidence, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 204 countries and territories from 1990 to 2023 by age and sex. The GBD 2023 estimates supersede previous estimates for all years. For mortality estimates, we fit a cause of death ensemble model to vital registration data. For non-fatal estimates in endemic locations, we did a systematic review of seroprevalence data, defining a confirmed case as a confirmed diagnosis of T cruzi infection by two different positive tests (or a single ELISA or immunochromatographic test). After adjustment for the population at risk, we used a Bayesian compartmental model (DisMod-MR) to produce estimates. For non-endemic locations, we estimated prevalence on the basis of migration patterns and estimated prevalence from endemic countries. Prevalence of acute and chronic sequelae and corresponding disability weights were used to calculate YLDs. Findings: We estimated 10·5 million (95% uncertainty interval 9·4–11·7) Chagas disease prevalent cases in 2023 globally, a 16·1% (12·6–19·2) decrease compared with 1990. | |
| dc.identifier.citation | Cousin, E., Nascimento, B.R., Whisnant, J.L., Zimsen, S.R., Harris, A.A., Machado, I.E., Martins-Melo, F.R., Demacq, C., Perel, P., Geissbühler, Y. and Abbasi, M., 2026. Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Infectious Diseases, 26(3), pp.284-301. | |
| dc.identifier.uri | https://doi.org/10.1016/S1473-3099(25)00562-6 | |
| dc.identifier.uri | https://hdl.handle.net/10566/24694 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Ltd | |
| dc.relation.ispartofseries | N/A | |
| dc.subject | adolescent | |
| dc.subject | adult | |
| dc.subject | aged | |
| dc.subject | Chagas disease | |
| dc.subject | child | |
| dc.subject | preschool | |
| dc.subject | disability-adjusted life years | |
| dc.title | Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the global burden of disease study 2023 | |
| dc.type | Article |